Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2013

A review of cutaneous toxicities from targeted therapies in the
treatment of colorectal cancers
Christopher Urban
Washington University School of Medicine in St. Louis

Milan J. Anadkat
Washington University School of Medicine in St. Louis

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Urban, Christopher and Anadkat, Milan J., ,"A review of cutaneous toxicities from targeted therapies in the
treatment of colorectal cancers." Journal of Gastrointestinal Oncology. 4,3. 319-327. (2013).
https://digitalcommons.wustl.edu/open_access_pubs/1956

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Review Article

A review of cutaneous toxicities from targeted therapies in the
treatment of colorectal cancers
Christopher Urban, Milan J. Anadkat
Washington University of St. Louis School of Medicine, St. Louis, Missouri, USA
Corresponding to: Milan J. Anadkat, MD. Washington University Division of Dermatology, 660 S. Euclid, Campus Box 8123, St. Louis, MO 63110,
USA. Email: manadkat@dom.wustl.edu.

Abstract: Currently there are three targeted therapies approved for the treatment of colorectal cancers.
These include the epidermal growth factor receptor (EGFR) inhibitors, cetuximab and panitumumab, and
the multikinase inhibitor regorafenib. It is important to understand and recognize the common presentations
of cutaneous toxicity that result from these agents to effectively manage symptoms and prevent premature
discontinuation of anticancer treatment.
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Currently there are three targeted therapies approved
for the treatment of colorectal cancers. These include
the epidermal growth factor receptor (EGFR) inhibitors,
cetuximab and panitumumab, and the multikinase inhibitor
regorafenib. It is important to understand and recognize
the common presentations of cutaneous toxicity that result
from these agents to effectively manage symptoms and
prevent premature discontinuation of anticancer treatment.
EGFR inhibitors
Cetuximab and panitumumab are intravenous monoclonal
antibody EGFR inhibitors. Cetuximab was first FDAapproved in 2004 for metastatic colorectal carcinoma and
in 2012, it was approved as first-line treatment of KRAS
mutant-negative, EGFR-expressing metastatic colorectal
cancer. Panitumumab was first FDA-approved in 2006 for
the treatment of EGFR-expressing metastatic colorectal
cancer.
The most common cutaneous toxicity resulting from
treatment with EGFR inhibitors is the development of
an acneiform eruption. This consists of follicular sterile
pustules and papules usually involving the face, scalp,
and upper trunk (Figures 1,2,3). Secondary infections are
commonly observed, but must be confirmed by bacterial
culture. Histopathology shows folliculitis with collections
of neutrophils within the follicles and lymphocytes
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Figure 1 Acneiform rash affecting the face during EGFR inhibitor
treatment

surrounding the follicles. It is essential to understand that
this eruption resembles acne (hence the term “acneiform”),
but is actually not acne. This eruption lacks comedones
and does not respond to topical retinoids, both of which
are cornerstones of traditional acne vulgaris. The basic
differential diagnosis for the acneiform eruption induced
by EGFR inhibitors includes steroid induced acne and
infectious folliculitis caused by bacteria or yeast. Positive
correlations between the development of acneiform
eruptions and clinical outcomes have been observed so it
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Figure 2 Acneiform rash affecting the back during EGFR inhibitor

Figure 3 Acneiform rash affecting the chest during EGFR

treatment

inhibitor treatment

Table 1 Common Terminology Criteria for Adverse Events-Acneiform rash
Reaction
Rash

Grade 1
Papules/pustules

Grade 2

Grade 3

Grade 4

Papules/pustules

Papules/pustules covering >30% Papules/pustules covering any

covering 10-30% BSA;

BSA; limiting self care activities

percentage BSA; extensive

BSA; +/- pruritis or

psychosocial impact &

of daily living; associated with

superinfection with intravenous

tenderness

limiting instrumental

local superinfections with oral

antibiotics indicated;

activities of daily living

antibiotics indicated

life-threatening consequences

acneiform covering <10%

Grade 5
Death

Reproduced from the Common Terminology Criteria for Adverse Events version 4.0. (http://www.cancer.gov) (1)

is important to treat through these reactions and reserve
discontinuation of medication as a last resort.
The Common Terminology Criteria for Adverse Events
established by the National Cancer Institute defines the
severity of acneiform rash from grades one through five as
shown in Table 1.
Studies have been conducted to explore the pathogenesis
of the acneiform eruption caused by EGFR inhibitors.
The EGF receptor is present in keratinocytes in the
basal and suprabasal layers of the epidermis and the outer
layers of hair follicles. Stimulation of the EGFR pathway
promotes keratinocyte survival and proliferation. Han
et al. found increased expression of cytokines such as
interleukin-1 alpha, tumor necrosis factor-alpha, and
interferon-gamma in acneiform lesions of patients when
EGFR was inhibited by cetuximab. These increased
cytokines may lead to inflammation in the dermis. This
inflammation is characterized by neutrophilic inflammatory
infiltrates followed by follicular proliferation and plugging
that causes the papulopustular eruption. The mechanism
is distinct from the etiology of acne vulgaris, where
inflammation follows comedone formation. This explains
why topical steroids are an effective treatment for the severe
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papulopustular eruption caused by cetuximab but may
worsen acne vulgaris.
Most patients receiving cetuximab or panitumumab
(up to 90%) will develop the acneiform eruption within
the first two weeks of therapy (2,3). Tol et al. reported a
phase III study comparing toxicity of adding cetuximab to
a combination treatment with capecitabine, oxaliplatin and
bevacizumab (4). In the cohort not taking cetuximab only
7 of 197 experienced an acneiform skin rash. In the
cetuximab group 156 of 197 developed an acneiform skin
rash with fifty of these patients categorized as grades 3 or
4 severity. Patients on panitumumab have an increased
incidence of acneiform eruptions but similar clinical findings
when compared to the cutaneous toxicities induced by
cetuximab. Douillard et al. reported results of a phase III trial
of panitumumab with infusional fluorouracil, leucovorin,
and oxaliplatin (FOLFOX4) versus FOLFOX4 alone (5).
In the 545 patients treated with FOLFOX4 alone only
ten developed skin toxicity. Of patients treated with
panitumumab plus FOLFOX4 182 of 539 developed skin
toxicity.
Perez-Soler and Saltz were the first to report the
association of acneiform rash due to EGFR inhibitors as a
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surrogate marker for efficacy in 2005 (6). This association
only holds true for the acneiform rash due to EGFR
inhibitors. Other forms of EGFR inhibitor cutaneous
toxicity such as paronychia, hair and nail changes, and
xerosis discussed later are not considered markers for
efficacy. Multiple studies suggest that a positive correlation
exists between occurrence of an acneiform rash and both
the cancer’s response to the EGFR-targeted therapy and
patient survival. Since cutaneous toxicity may be associated
with improved clinical outcomes, it is important to avoid
stopping EGFR inhibitor treatments for cutaneous toxicities
and, instead, treat through eruptions. To better counsel
patients about the risks of the cutaneous toxicities of EGFR
inhibitors, Jatoi et al. evaluated whether any patients have
died from rashes caused by EGFR inhibitors (7). After
reviewing 117 trials including 8,998 cancer patients where
the rate of rash development was greater than 50%, they
concluded that there were no reported rash-related deaths.
In addition to the physical effects of EGFR inhibitors,
several researchers addressed the psychological and
emotional effects of cutaneous toxicity. Romito et al.
studied the psychological effect of the cutaneous skin rash
in eighty advanced colorectal cancer patients treated with
cetuximab (8). Forty-one percent reported psychological
distress caused by the rash. When questioned about how
the rash affected the willingness of patients to go out into
public, 22% “very much” avoided going out and 25%
“somewhat” avoided going out. In addition to the cosmetic
effects, a significant psychological and quality of life effect
from these eruptions results from physical symptoms of
burning, stinging, and itching (9). It is, therefore, clear that
treating the cutaneous toxicities of EGFR inhibitors not
only allows patients to continue on potentially life saving
oncology treatments but also can greatly improve their
quality of life.
Several authors have reviewed treatments of the
cutaneous toxicity associated with EGFR inhibitor
receptors. Jatoi et al. conducted a randomized, doubleblinded placebo controlled study with 65 patients
comparing tetracycline 500 mg orally twice per day for
28 days versus placebo (10). Monitoring was done for
the four weeks of treatment and an additional four weeks
with primary objective to compare incidence of grade 2 or
worse rash between the groups. This study found that oral
tetracycline did not significantly lessen rash incidence or
severity in patients taking EGFR inhibitors. Scope et al.
conducted a randomized double-blind controlled trial of
oral minocycline for cetuximab induced acneiform eruption
published in 2007 (11). Of 48 patients enrolled, half were
randomly assigned to minocycline and the other half to
placebo for 8 weeks of treatment. Total facial lesion counts
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were significantly lower for patients receiving treatment
rather than placebo at week one through four. At week four
patients in the minocycline treatment group had a lower
frequency of moderate to severe rash than patients receiving
placebo and at week eight there were diminished total
facial lesion counts. No patients treated with minocycline
had to discontinue cetuximab treatment due to acneiform
eruption but four patients in the placebo group had to
interrupt treatment because of grade 3 skin rash. Topical
tazarotene use was also studied. Tazarotene was not helpful
in controlling the acneiform rash and caused significant
irritation, supporting the observation that this condition
does not respond like traditional acne vulgaris.
De Noronha et al. reviewed the management of
cutaneous side effects during erlotinib and cetuximab
treatment in lung and colorectal cancer patients (12). They
presented a treatment algorithm to help manage these
patients. Upon initiation of treatment with the EGFR
inhibitor they started patients on daily sunscreen, mild skin
cleanser, and moisturizing cream. In patients who developed
mild acneiform eruptions they began topical antibiotics plus
topical benzoyl peroxide. For patients who developed grade
2 or 3 cutaneous reactions they started oral doxycycline
or minocycline at a dose of 100 mg/day. In one case that
was not responsive to oral antibiotics they initiated oral
low dose isotretinoin. Antihistamines were recommended
when patients experienced pruritis. In the nineteen cases
described by these authors none had to stop EGFR
inhibitor treatment because of cutaneous side effects, all but
one patient showed improvement on oral antibiotics, and
42% experienced a complete response.
The skin toxicity evaluation protocol with panitumumab
(STEPP) study conducted by Lacouture et al. was a
randomized trial evaluating pre-emptive versus reactive
treatment with doxycycline for patients receiving
panitumumab (13). All patients started a standard regimen
of daily skin moisturizer, sunscreen, and topical steroid
at the onset of chemotherapy. Forty-eight patients also
received pre-emptive treatment with doxycycline 100 mg
twice per day, while forty-seven received doxycycline
only after skin toxicity developed. The incidence of grade
2 skin toxicities during the six-week treatment period was
29% for the pre-emptive treatment group and 62% for the
reactive treatment group. The pre-emptive treatment with
doxycycline was well tolerated and patients in this group
reported less impairment of quality of life.
Requena et al. reported three cases of severe acneiform
eruptions induced by EGFR inhibitors that were
successfully treated to the point of complete response with
oral isotretinoin (14). In data pending publication, we
have also had success with over a dozen patients using oral
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Figure 4 Fissure on finger developed during EGFR inhibitor

Figure 5 Paronychia with periungual pyogenic granuloma-like

treatment

lesions associated with EGFR inhibitor treatment

isotretinoin to successfully treat cases of severe acneiform
eruptions caused by EGFR inhibitors (15).
Other cutaneous toxicities can be observed during
treatment with EGFR inhibitors. Patients may develop
xerosis and painful fissuring (Figure 4). As described by Han
et al. EGFR inhibitor use leads to abnormal differentiation
of keratinocytes with decreased levels of filaggrin and
loricrin (16). These are both components of the outer skin
layer known as the stratum corneum and play a role in the
retention of moisture. Decreased levels of these proteins
may explain the xerosis observed in the cutaneous EGFR
induced drug rashes. Rodríguez-Murphy et al. studied a
group of forty-three patients treated with cetuximab and
observed xerosis in less than a quarter of patients after a
mean delay of 40 days (17). Three patients in this group
developed painful fissures on the hands and feet. Xerosis is
actually much more common though and likely the followup in this study was not adequate for assessment. In 2009,
Osio et al. reported a study describing the cutaneous sideeffects in sixteen patients on long-term treatment with
epidermal growth factor receptor inhibitors with the range
of follow-up from 6 to 27 months and mean treatment
10 months and found xerosis present in all patients (18). All
patients should be counseled on dry skin care prevention
with lukewarm showers or baths, minimal soap usage
(primarily axilla, groin, and feet), and thick emollient
usage daily. Fissures are best treated with super glue for
immediate closure.
Patients on EGFR inhibitors may develop nailfold
changes after two or more months of treatment. These
most commonly include nailfold inflammation (paronychia)
and periungual pyogenic granuloma-like lesions (Figure 5).
As a secondary processes resulting from nail matrix
inflammation, the nails can become dystrophic or the nail
plates may lift from the nail beds (onycholysis). Trauma

is not required to precede the changes but is likely an
aggravating factor. Both fingernails and toenails can be
affected and the first digits are most commonly affected.
The affected digits are painful and morbidity may be high
due to impaired functionality limiting activities of daily
living. Rodríguez-Murphy et al. studied a group of fortythree patients treated with cetuximab and found that two
developed paronychia (17).
Although paronychia is often sterile, lesions may become
superinfected so culturing the lesion is recommended
for appropriate antimicrobial selection and treatment.
Lacouture et al. described a retrospective study of
152 patients treated with cetuximab in which 27 cases
of paronychia developed for an incidence of 17.7% (19).
Forty-two culture swabs were performed and all cultures
grew some organisms. Nosocomial colonization with
coagulase-negative gram-positive bacteria was found in
31% and Staphylococcus aureus infection was found in
23%. Recommendations for minimizing periungual trauma
include comfortable shoes, keeping nails trimmed but
avoiding aggressive manicuring, and wearing gloves for
protection while cleaning and doing housework. Topical
corticosteroids and anti-inflammatory doses of tetracyclines
may help decrease periungual inflammation while
antimicrobial soaks such as dilute bleach in water or dilute
white vinegar in water can prevent superinfection.
The periungual pyogenic granuloma-like lesions
clinically appear as friable vascular tissue overgrowth and
commonly bleed. Local trauma may precede development of
the lesions or aggravate them leading to increased symptoms
of bleeding. Santiago et al. studied fourteen patients on
EGFR inhibitors cetuximib or erlotinib and observed that
five patients developed periungual pyogenic granulomas
and four of these patients also had paronychia (20).
The pyogenic granulomas occurred an average of eight
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Figure 7 Cutaneous bacterial superinfection during EGFR
inhibitor treatment

Figure 6 Trichomegaly during EGFR inhibitor treatment

weeks after beginning treatment. Medical intervention may
be necessary to eliminate excessive granulation tissue and
treatment options include electrocautery, silver nitrate, and
nail avulsion.
Abnormalities of the hair can develop in patients taking
EGFR inhibitors. Patients may experience hypertrichosis
or increased hair growth. Specifically, increased hair growth
of the eyebrows and eyelashes (trichomegaly) may occur
(Figure 6). Patients can also develop scalp alopecia, which
may be scarring or nonscarring.
Cutaneous superinfections can complicate the cutaneous
toxicities affecting patients treated with EGFR inhibitors
(Figure 7). Several studies have been conducted to explore
the microbiology of these infections. Amitay-Laish et al.
studied 29 patients on EGFR inhibitors cetuximab or
erlotinib and found that 24 patients had a papulopustular
reaction (21). They divided this cohort into two groups
based on when they developed the papulopustular eruption.
The early phase group contained seventeen patients and
had a median onset at 8 days. The late phase group had
a median onset at 200 days and contained seven patients.
Staphylococcus aureus was found in 7 of 13 early phase
patients and in all 7 late phase patients. The high incidence
of staphylococcal infection demonstrates the importance
of bacterial cultures in the assessment and treatment of
EFGR inhibitor eruptions. This study also emphasizes the
importance of seeking a pathogenic microbial cause when
patients who were stable on the EGFR inhibitors develop
a late onset papulopustular reaction. Eilers et al. studied
221 patients treated with EGFR inhibitors and found
that 84 showed evidence of infection at the sites of the
cutaneous toxicity (22). Cultures revealed that fifty were
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positive for Staphylococcus aureus and twelve were positive
for methicillin-resistant Staphylococcus aureus. Other less
common infections included herpes simplex, herpes zoster,
and dermatophytes. Occasionally uncommon pathogens
can be identified in patients taking EGFR inhibitors,
as demonstrated by Bark et al. who reported a case of
disseminated cutaneous Mycobacterium chelonae in a
patient with head and neck cancer on salvage chemotherapy
with cetuximab (23). This reinforces the value of bacterial
cultures to determine specific pathogenic agents in cases
that are not responding to typical treatment regimens.
Our treatment algorithm begins with examining
patients in clinic either before or soon after starting
EGFR inhibitors but preceding the development of
significant cutaneous toxicity. Patients are instructed
to use sunscreen and dry skin care is reviewed with an
emphasis placed on using emollients such as Vaseline
or thick body creams regularly. Topical steroids can
be prescribed such as triamcinolone 0.1% cream or
ointment for use once to twice per day as needed for
itchy scaly red rashes. Oral antibiotics are started when
chemotherapy is initiated, prior to rash development,
to prevent or minimize the acneiform eruption. The
usual treatment consists of minocycline 50 or 100 mg
twice per day and side effects such as headache, dizziness,
hypersensitivity reaction, and drug-induced rash are
reviewed. Patients are instructed to stop the medication
immediately if a new rash or other side effect develops.
Another option for treatment is doxycycline 50 or 100 mg
twice per day and side effects of gastrointestinal upset and
photosensitivity are reviewed. Patients are instructed to
take the pills with food and a full glass of water to limit
the gastrointestinal side effects. When lesions persist
or worsen despite treatment with oral antibiotics and
topical steroids it may helpful to rule out superinfection.
When infection is absent in the setting of a difficult to
manage acneiform eruption, the practitioner should
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Figure 8 Hyperkeratotic plaques on areas of friction from
regorafenib

Figure 9 Hyperkeratotic plaque on thumb from regorafenib

start oral isotretinoin. If the practitioner is uncomfortable
prescribing or managing treatment with oral isotretinoin,
referral to a dermatologist with knowledge of EGFR
inhibitor induced cutaneous toxicities may be beneficial
for the initiation of treatment.

It is associated with HFSR and splinter hemorrhages plus
hair depigmentation, skin discoloration, and neutrophilic
dermatoses.
HFSR can occur with regorafenib, and has long been a
known side effect of multikinase inhibitors such as sorafenib
and sunitinib. HFSR from multikinase inhibitors is a unique
cutaneous toxicity pattern that should be distinguished
from acral erythema (also known as hand foot syndrome
and palmoplantar dysthesthesia) seen with classic cytotoxic
chemotherapy. Patients with HFSR from multikinase
inhibitors experience acral pain and dysesthesia, but usually
to a lesser extent and with less edema than when caused by
chemotherapy agents such as 5-flourouracil, doxorubicin,
and cytosine arabinoside. The most characteristic feature
of HFSR is the development of palmar and plantar
hyperkeratotic plaques (Figures 8,9). These occur most often
over areas of friction. During treatment with sorafenib and
sunitinib, high grade hand-foot skin reactions have been
reported to occur in up to 9% of cases resulting in impaired
functionality from blisters and ulceration (27). Nardone
et al. found these drug induced hand-foot skin reactions
negatively impacted the patients’ health-related quality of
life scores (28).
Hand and foot skin reactions are known to occur
in patients receiving regorafenib for the treatment of
metastatic adenocarcinoma of the colon. Often several
weeks after starting the medication painful blistering plaques
or rash develop on the feet and tender thickened plaques
may develop on fingertips. This rash may affect activities
of daily living because of the blistering, thickening, and
discomfort that is frequently most severe at pressure points
such as balls of the feet and fingertips. In clinical trials
treating gastrointestinal stromal tumors with regorafenib,
Demetri et al. reported that 20% of patients (26 of 132)

Regorafenib
The newest targeted therapy approved for the treatment of
colorectal cancers is the multikinase-inhibitor regorafenib.
Regorafenib is an oral multikinase inhibitor that targets
vascular endothelial growth factor receptor 2, plateletderived growth factor receptor-β, fibroblast growth factor
receptor 1, C-KIT, RET, and B-RAF (24). Regorafenib is
currently being studied for use in gastrointestinal stromal
tumors (GIST), colorectal carcinoma, and renal cell
carcinoma. While similar to older multikinase inhibitors
such as sorafenib and sunitinib, regorafenib also has
structurally and biologically unique properties allowing for
its use when tumors become resistant to these older agents.
Phase III clinical trials of regorafenib in gastrointestinal
stromal tumors that developed resistance to imatinib
and sunitinib have shown increased medial progression
free survival compared to placebo (25). Similarly, in
colorectal cancer median overall survival was 6.4 months
in the regorafenib group versus 5 months in the placebo
group (26). We will review the side effects of similar
multikinase-inhibitors, sorafenib and sunitinib, and present
what is known to date to occur from Regorafenib. Sorafenib
targets B-RAF, VEGF-2, C-KIT, fetal liver TK(Flt)-3,
and PDGFR. It is associated with hand-foot skin reaction
(HFSR) and splinter hemorrhages as well as a seborrhea-like
facial rash and a follicular rash on the trunk and extremities.
Sunitinib targets VEGF-2, C-KIT, Flt-3, and PDGFR.

© Pioneer Bioscience Publishing Company. All rights reserved.

www.thejgo.org

J Gastrointest Oncol 2013;4(3):319-327

Journal of Gastrointestinal Oncology, Vol 4, No 3 Sep 2013

325

Figure 11 Follicular keratotic papules associated with multikinaseFigure 10 Seborrheic dermatitis-like rash developed during

inhibitor treatment

regorafenib treatment

Figure 12 Development of squamous cell carcinoma during
treatment with vemurafenib (BRAF-inhibitor)

developed a hand-foot skin reaction (25). In clinical trials
treating colorectal cancer with regorafenib, Grothey et al.
observed grade three or higher hand-foot skin reactions in
17% of patients (83 of 500) (26).
Management of the HFSR can be challenging but the
basic principles include minimizing friction and trauma
with comfortable well fitting shoes and protective gloves.
Topical corticosteroids can minimize inflammation and
thickened hyperkeratotic plaques on the hands and feet can
be softened with the use of keratolytic creams such as urea
or lactic acid. Dose reduction of the regorafenib is another
option for reducing the bothersome side effects. Unlike
with the acneiform eruption seen with EFGR inhibitors,
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there is no known correlation of the HFSR rash or any
other cutaneous toxicity from regorafenib to efficacy of the
medication.
A seborrheic dermatitis-like rash may occur while taking
multikinase inhibitors, including regorafenib (Figure 10).
The seborrhea-like facial rash can typically be controlled
with topical medications. Low potency corticosteroids such
as hydrocortisone 2.5% cream or ketoconazole cream may
be beneficial.
A follicular rash may develop during treatment with
multikinase inhibitors as described by Lopez et al. (29).
Clinically this manifests as skin colored to erythematous
follicular keratotic papules (Figure 11). Histopathology
s h o w s p r o m i n e n t f o l l i c u l a r h y p e r p l a s i a . To p i c a l
corticosteroids or topical keratolytics may be helpful for
symptomatic control.
Cutaneous squamous cell carcinoma and the
inflammation of actinic keratoses were reported to be
associated with sorafenib in 2009 by Dubauskas et al. (30).
In 131 patients treated with sorafenib for metastatic
renal cell carcinoma, seven cases of cutaneous squamous
cell carcinoma and two cases of keratoacanthoma type
squamous cell carcinoma were reported. In 2013, Breaker
et al. reported an association with skin cancer and the use
of sorafenib and sunitinib for renal cell carcinoma (31).
Of 69 patients treated with multikinase inhibitors, five
patients on sorafenib and two patients on sunitinib
developed skin cancers, of which five lesions were
squamous cell carcinomas and three lesions were basal
cell carcinomas. The median treatment durations before
identification of the skin cancer was longer than one year.
Figure 12 shows a squamous cell carcinoma that developed
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during treatment with a multikinase-inhibitor. The BRAF
inhibitor vemurafenib is used in the treatment of metastatic
melanoma. Vemurafenib also triggers the development of
squamous cell carcinomas possibly through the activation of
wild-type RAF in sun-damaged keratinocytes. Long-term
follow-up of regorafenib treatment will be necessary to
determine if similar cutaneous skin cancer risks exist.
These findings highlight how familiarity with the
characteristic skin reactions observed in classes or families
of targeted chemotherapeutics may help predict what
reactions to expect from new agents. Knowledge of the
presentation and treatment of the cutaneous toxicities
caused by targeted therapies approved for the treatment of
colorectal cancers is extremely important for the practicing
oncologist and dermatologist. Successful treatment
improves patients’ quality of life while undergoing these
therapies. It addition, by minimizing the cutaneous side
effects patients experience these life-saving treatments can
be continued at the proper doses and durations to allow for
the most effective treatment of their cancers.
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